Development of a novel oncolytic adenovirus controlled by CDX2 promoter for esophageal adenocarcinoma therapy.

Naohiko NakamuraShuhei ShinodaMizuho Sato-DahlmanBrett RoachKari JacobsenMasato Yamamoto

Published in: Journal of gastroenterology (2024)

Ad5/3-pCDX2 showed specific anticancer effect for EAC, which was enhanced by bile acid exposure. Ad5/3-pCDX2 has promising potential for EAC therapy in the clinical setting.

Keyphrases

dna methylation
squamous cell carcinoma
gene expression
stem cells
radiation therapy
locally advanced
bone marrow
gene therapy